Targeted Blood Brain Barrier Permeability Changes with Ultrasound &Microbubbles

Information

  • Research Project
  • 7328285
  • ApplicationId
    7328285
  • Core Project Number
    R41NS057860
  • Full Project Number
    1R41NS057860-01A1
  • Serial Number
    57860
  • FOA Number
    PA-06-21
  • Sub Project Id
  • Project Start Date
    9/1/2007 - 17 years ago
  • Project End Date
    8/31/2008 - 16 years ago
  • Program Officer Name
    GRABB, MARGARET C.
  • Budget Start Date
    9/1/2007 - 17 years ago
  • Budget End Date
    8/31/2008 - 16 years ago
  • Fiscal Year
    2007
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    8/20/2007 - 17 years ago
Organizations

Targeted Blood Brain Barrier Permeability Changes with Ultrasound &Microbubbles

[unreadable] DESCRIPTION (provided by applicant): Ultrasound mediated destruction (UMD) of intravenously injected microbubbles has the potential to alter blood brain barrier (BBB) permeability at selective locations within the central nervous system. This selective alteration in BBB permeability could have significant therapeutic potential in targeting drug delivery for primary or metastatic central nervous system tumors, as well as neuro-degenerative disorders such as Alzheimer's dementia or Parkinson's Disease. However, the lower frequencies and longer duty cycles of non-imaging therapeutic ultrasound transducers increase the risk for deleterious bioeffects such as peri-vascular hemorrhage and endothelial injury. New diagnostic ultrasound transducers have increased sensitivity for the detection of microbubbles which can then be utilized to guide the delivery of brief high mechanical index impulses only when a maximal concentration of microbubbles are present. In the Phase I proposal of this application we will test the hypothesis that transtemporal guided diagnostic ultrasound can safely enhance delivery of chemotherapeutic agents conjugated to microbubbles across the blood brain barrier. This will be achieved by quantifying the magnitude, spatial distribution, and duration of enhanced BBB permeability induced by guided diagnostic ultrasound when compared to a therapeutic ultrasound transducer. The ability of guided diagnostic ultrasound transducers to enhance the delivery of two different chemotherapeutic agents of different molecular weight conjugated to the microbubbles into the cerebrospinal fluid will then be examined. These foundational studies will then provide the basis for a Phase II STTR proposal utilizing guided UMD of microbubbles in the treatment of primary and metastatic central nervous system tumors. In this project, the investigators will try to determine if ultrasound similar to what is used for routine diagnostic imaging can be used with ultrasound contrast agents (termed microbubbles) to briefly alter the ability of drugs to reach into brain tissue (across the blood brain barrier). This will allow us to target the delivery of drugs to the brain that could potentially be used to treat brain cancer or dementia (Alzheimer's Disease). [unreadable] [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R41
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    442339
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:442339\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    IMARX THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
    782996045
  • Organization City
    TUCSON
  • Organization State
    AZ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    85719
  • Organization District
    UNITED STATES